Mallinckrodt to acquire Sucampo Pharmaceuticals in $1.2bn deal
In a strategic move to broaden its pharmaceutical offerings, UK-based Mallinckrodt has announced the acquisition of Sucampo Pharmaceuticals, including its commercial and developmental assets, for approximately $1.2 billion. This acquisition also involves the assumption of $360 million of Sucampo’s debt, signaling a significant investment by Mallinckrodt into expanding its specialty pharmaceutical and rare disease sectors. […]